Press release
Importivity Facilitates Record-Breaking Growth in Clients Buying in Bulk from China, Countering Media Narrative of U.S.-China Trade Decline
Austin, TX - July 30, 2025 - In direct contrast to prevalent media reports claiming U.S.-China trade relations are deteriorating, Importivity, a leading global sourcing and logistics consulting firm based in Austin, Texas, today announced a remarkable 422% year-over-year increase in bulk imports from China for their U.S. clients during the second quarter of 2025.While mainstream headlines frequently discuss the negative impact of tariffs and trade uncertainties, Importivity's clients have strategically leveraged current conditions to substantially grow their inventory positions. "We've seen a substantial uptick in businesses proactively buying in bulk from China," explains Jordan Lewis, Chief Operating Officer at Importivity. "While some of this growth naturally correlates with our clients' own expansion and market success, much of it reflects a savvy, strategic effort to capitalize on the current tariff pause. Companies recognize this moment as a golden window of opportunity to secure inventory at reasonable duty rates and buy themselves critical time to diversify their sourcing strategies.
Image: https://www.abnewswire.com/upload/2025/07/71940162bca796e9a534b06cb5ab9cb1.jpg
Importivity's CEO and COO at the 2025 Canton Fair in Guangzhou, China.
"Lewis highlights how the first quarter of 2025 presented significant challenges, stating: "Q1 hit our clients hard. Businesses were understandably nervous, prompting frantic calls about supply chain strategies and tariff impacts. Fortunately, at Importivity, we anticipated these scenarios as early as November of last year and developed detailed, customized contingency plans for each client. We even made strategic investments in partner facilities in Vietnam to offer trusted alternatives and diversify our clients' supply chain networks."
The firm's comprehensive strategy notably paid off for numerous clients. For example, Importivity recently assisted a client who had over $2 million worth of taxable goods stuck in transit at Long Beach port. Leveraging expert compliance knowledge, Importivity swiftly identified and filed under relevant legal exemptions, including HTSUS Chapter 98 (U.S. Goods Returned) and Section 321 de minimis entries, resulting in substantial cost savings and rapid cargo clearance, a major relief to the client's supply chain operations.
Deedee Patterson, founder of Whiskey Towers, an innovative liquor dispenser brand and Importivity client, directly challenges popular negative narratives regarding tariffs: "Our business has experienced no significant negative impact from tariffs. Yes, we've noticed some incremental increases in product costs, but our margins remain strong due to dramatically increased sales volumes. Frankly, the strength of consumer demand more than offsets these incremental tariff-related costs. To us, this signals a very healthy, robust economy, not a struggling one."
Lewis describes the second quarter of 2025 as transformational: "Closing Q2 feels akin to stepping off a roller coaster. After a challenging Q1, we saw unprecedented record imports from China. The tariff pause has given our clients a critical advantage, enabling them to stockpile inventory effectively and granting them the breathing room necessary to formulate robust long-term sourcing strategies." Expressing cautious optimism about future U.S.-China trade relations, Lewis notes: "I'm genuinely optimistic that the United States and China will ultimately reach a mutually beneficial trade agreement. Still, at Importivity, we never rely solely on optimism-we encourage our clients to act strategically. Smart businesses are making bold moves today, proactively securing inventory and diversifying their sourcing to stay ahead of any future trade disruptions."
About Importivity
Importivity is a premier global sourcing and logistics firm dedicated to simplifying and optimizing international procurement processes. Specializing in helping U.S. brands securely navigate the complexities of buying in bulk from China, Vietnam, and Mexico, Importivity offers customized solutions in product sourcing, compliance, tariff mitigation, quality assurance, and streamlined logistics.
Brands interested in learning how they can secure their inventory, mitigate risks, and explore global sourcing opportunities are encouraged to schedule a complimentary strategy call at: https://book.bizeebay.com/#/importivity-consultation
For further details about Importivity's China sourcing capabilities, please visit: https://importivity.com/connections/buying-in-bulk-from-china/
Media Contact
Company Name: Importivity LLC
Contact Person: Lila Monroe - Head of Communications
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=importivity-facilitates-recordbreaking-growth-in-clients-buying-in-bulk-from-china-countering-media-narrative-of-uschina-trade-decline]
Phone: +1 (877) 570-6930
Country: United States
Website: https://importivity.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Importivity Facilitates Record-Breaking Growth in Clients Buying in Bulk from China, Countering Media Narrative of U.S.-China Trade Decline here
News-ID: 4127118 • Views: …
More Releases from ABNewswire

Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…

Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…

Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…

Retinal Vein Occlusion Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Retinal Vein Occlusion Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Retinal Vein Occlusion pipeline landscape. It covers the Retinal Vein Occlusion pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Retinal Vein Occlusion pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…